Pazdur On Accelerated Approval: FDA Needs To Explain Why It Does Not Always Seek Withdrawal When Trials Fail

Knee-jerk reaction when a confirmatory trial fails is that the drug should be withdrawn, but the agency must undertake a more nuanced evaluation and do a better job explaining it to the public, OCE Director Richard Pazdur says; Pazdur and Project Confirm lead Gautam Mehta spoke with the Pink Sheet about dangling indications, FDORA reforms and the withdrawal process.

knee
A nuanced approach, rather than a knee-jerk reaction, is needed in deciding whether to pull an accelerated approval drug with a failed confirmatory trial. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards